Eryptosis as a marker of Parkinson's disease

被引:80
作者
Pretorius, Etheresia [1 ]
Swanepoel, Albe C. [1 ]
Buys, Antoinette V. [2 ]
Vermeulen, Natasha [1 ]
Duim, Wiebren [3 ]
Kell, Douglas B. [4 ,5 ]
机构
[1] Univ Pretoria, Fac Hlth Sci, Dept Physiol, ZA-0007 Arcadia, South Africa
[2] Univ Pretoria, Microscopy & Microanal Unit, ZA-0007 Arcadia, South Africa
[3] Univ Pretoria, Fac Hlth Sci, Dept Neurol, ZA-0007 Arcadia, South Africa
[4] Univ Manchester, Sch Chem, Manchester M1 7DN, Lancs, England
[5] Univ Manchester, Manchester Inst Biotechnol, Manchester M1 7DN, Lancs, England
来源
AGING-US | 2014年 / 6卷 / 10期
基金
英国生物技术与生命科学研究理事会; 新加坡国家研究基金会;
关键词
Parkinson's disease; hypercoagulability; erythrocytes; eryptosis; SCANNING-ELECTRON-MICROSCOPY; QUALITY-OF-LIFE; NF-KAPPA-B; MONOAMINE-OXIDASE INHIBITORS; DRUG SAFETY EVALUATION; BRAIN IRON DEPOSITION; RED-BLOOD-CELLS; OXIDATIVE DAMAGE; ULTRASTRUCTURAL-CHANGES; ALZHEIMERS-DISEASE;
D O I
10.18632/aging.100695
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
A major trend in recent Parkinson's disease (PD) research is the investigation of biological markers that could help in identifying at-risk individuals or to track disease progression and response to therapies. Central to this is the knowledge that inflammation is a known hallmark of PD and of many other degenerative diseases. In the current work, we focus on inflammatory signalling in PD, using a systems approach that allows us to look at the disease in a more holistic way. We discuss cyclooxygenases, prostaglandins, thromboxanes and also iron in PD. These particular signalling molecules are involved in PD pathophysiology, but are also very important in an aberrant coagulation/hematology system. We present and discuss a hypothesis regarding the possible interaction of these aberrant signalling molecules implicated in PD, and suggest that these molecules may affect the erythrocytes of PD patients. This would be observable as changes in the morphology of the RBCs and of PD patients relative to healthy controls. We then show that the RBCs of PD patients are indeed rather dramatically deranged in their morphology, exhibiting eryptosis (a kind of programmed cell death). This morphological indicator may have useful diagnostic and prognostic significance.
引用
收藏
页码:788 / 819
页数:32
相关论文
共 315 条
[1]   Prevalence of haemochromatosis gene mutations in Parkinson's disease [J].
Aamodt, Anne Hege ;
Stovner, Lars Jacob ;
Thorstensen, Ketil ;
Lydersen, Stian ;
White, Linda R. ;
Aasly, Jan O. .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2007, 78 (03) :315-317
[2]   Enterobactin protonation and iron release: Structural characterization of the salicylate coordination shift in ferric enterobactin [J].
Abergel, Rebecca J. ;
Warner, Jeffrey A. ;
Shuh, David K. ;
Raymond, Kenneth N. .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2006, 128 (27) :8920-8931
[3]   Anti-Parkinson's disease drugs and pharmacogenetic considerations [J].
Agundez, Jose A. G. ;
Garcia-Martin, Elena ;
Alonso-Navarro, Hortensia ;
Javier Jimenez-Jimenez, Felix .
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2013, 9 (07) :859-874
[4]   Monoamine Oxidase Inhibitors and Neuroprotection: A Review [J].
Al-Nuaimi, Saleem K. ;
MacKenzie, Erin M. ;
Baker, Glen B. .
AMERICAN JOURNAL OF THERAPEUTICS, 2012, 19 (06) :436-448
[5]   Parkinson's disease risk factors: genetic, environmental, or both? [J].
Allam, MF ;
Del Castillo, AS ;
Navajas, RFC .
NEUROLOGICAL RESEARCH, 2005, 27 (02) :206-208
[6]   Iron Toxicity in Diseases of Aging: Alzheimer's Disease, Parkinson's Disease and Atherosclerosis [J].
Altamura, Sandro ;
Muckenthaler, Martina U. .
JOURNAL OF ALZHEIMERS DISEASE, 2009, 16 (04) :879-895
[7]  
Amor S., 2013, IMMUNOLOGY
[8]   Emerging roles of PGE2 receptors in models of neurological disease [J].
Andreasson, Katrin .
PROSTAGLANDINS & OTHER LIPID MEDIATORS, 2010, 91 (3-4) :104-112
[9]   Antiplatelet and Anticoagulant Therapy for Atherothrombotic Disease: The Role of Current and Emerging Agents [J].
Angiolillo, Dominick J. ;
Ferreiro, Jose Luis .
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2013, 13 (04) :233-250
[10]  
[Anonymous], 2013, Treat Guidel Med Lett, V11, P101